Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
Perspective Therapeutics, Inc. (CATX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field
Perspective Therapeutics to Provide Several Upcoming Corporate Updates
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
Perspective Therapeutics to Participate in Upcoming Investor Conferences
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
Profusa (NASDAQ:PFSA) and Perspective Therapeutics (NASDAQ:CATX) Financial Contrast
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Comparing Perspective Therapeutics (NASDAQ:CATX) & Biosig Technologies (NASDAQ:STEX)
Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space
Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Down 4.4% – Time to Sell?
Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of “Buy” by Brokerages
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Critical Survey: Perspective Therapeutics (NASDAQ:CATX) & Vyome (NASDAQ:HIND)
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of “Buy” from Brokerages
Perspective Therapeutics to Participate in Upcoming December Conferences
Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results
Perspective Therapeutics to Participate in Upcoming November Conferences
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results
Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript
Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025
Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors
Perspective Therapeutics to Participate in Upcoming September Conferences
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results
Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results
Perspective Therapeutics to Participate in Upcoming May Investor Conferences
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround
Perspective Therapeutics to Participate in Upcoming April Investor Conferences
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results